In individuals who started antiretroviral therapy during acute HIV infection, the proliferative capacity of HIV-specific CD8+ ...
Editing CAR T cells to produce inflammatory cytokines helps them enter solid tumors and promote cancer killing.
SAN DIEGO and SUZHOU, China, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company ...
Platelets are small, anucleate blood cells that play an essential role in hemostasis. Their primary task is to recognize vascular injury, become activated, and aggregate via their surface receptor ...
Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces the ...
BOSTON, Jan. 20, 2026) ("Tiziana"), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces the peer-reviewed publication of ...
Antengene Corporation Limited ('Antengene', SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or ...
Dr. Charles Cai, Chief Medical Officer of Leads Biolabs, stated: ...
Eureka Therapeutics, Inc., a clinical-stage biotechnology company advancing next-generation T-cell therapies for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted ...
Phase 1/2a study with lead Radio-DARPin MP0712 initiated; first patient dosing expected Q1 2026, initial data anticipated in 2026Full imaging and dosimetry data from MP0712 compassionate care program ...
IM1240 demonstrated improved safety in a toxicology study at doses up to 300-fold higher than a non-capped comparator ...
The CEO of ModeX Therapeutics discusses MDX2003, a groundbreaking tetraspecific therapy that promises enhanced efficacy and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results